Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Clinical Pathology
Published in: BMC Clinical Pathology 1/2011

Open Access 01-12-2011 | Technical advance

Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue

Authors: Jeffrey R Shuster, Raymond S Lance, Dean A Troyer

Published in: BMC Clinical Pathology | Issue 1/2011

Login to get access

Abstract

Background

Histopathology is the standard method for cancer diagnosis and grading to assess aggressiveness in clinical biopsies. Molecular biomarkers have also been described that are associated with cancer aggressiveness, however, the portion of tissue analyzed is often processed in a manner that is destructive to the tissue. We present here a new method for performing analysis of small molecule biomarkers and histology in exactly the same biopsy tissue.

Methods

Prostate needle biopsies were taken from surgical prostatectomy specimens and first fixed, each in a separate vial, in 2.5 ml of 80% methanol:water. The biopsies were fixed for 24 hrs at room temperature and then removed and post-processed using a non-formalin-based fixative (UMFIX), embedded, and analyzed by hematoxylin and eosin (H&E) and by immunohistochemical (IHC) staining. The retained alcohol pre-fixative was analyzed for small molecule biomarkers by mass spectrometry.

Results

H&E analysis was successful following the pre-fixation in 80% methanol. The presence or absence of tumor could be readily determined for all 96 biopsies analyzed. A subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining. To demonstrate the suitability for analysis of small molecule biomarkers, 28 of the alcohol extracts were analyzed using a mass spectrometry-based metabolomics platform. All extracts tested yielded successful metabolite profiles. 260 named biochemical compounds were detected in the alcohol extracts. A comparison of the relative levels of compounds in cancer containing vs. non-cancer containing biopsies showed differences for 83 of the compounds. A comparison of the results with prior published reports showed good agreement between the current method and prior reported biomarker discovery methods that involve tissue destructive methods.

Conclusions

The Molecular Preservation by Extraction and Fixation (mPREF) method allows for the analysis of small molecule biomarkers from exactly the same tissue that is processed for histopathology.
Appendix
Available only for authorised users
Literature
1.
Parikh K, Peppelenbosch MP: Kinome profiling of clinical cancer specimens. Cancer Res. 70 (7): 2575-2578.
2.
Henson DE: Back to the drawing board on immunohistochemistry and predictive factors. J Natl Cancer Inst. 2005, 97 (24): 1796-1797. 10.1093/jnci/dji449.CrossRefPubMed
3.
Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, Dallenbach FE, Fischer HP, Mengel M, von Wasielewski R, Muller-Hermelink HK: Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol. 2002, 26 (7): 873-882. 10.1097/00000478-200207000-00005.CrossRefPubMed
4.
Rhodes A, Jasani B, Balaton AJ, Miller KD: Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000, 53 (4): 292-301. 10.1136/jcp.53.4.292.CrossRefPubMedPubMedCentral
5.
Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A: The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004, 122 (1): 51-60. 10.1309/E9B55JYHD84L8Y17.CrossRefPubMed
6.
Fox CH, Johnson FB, Whiting J, Roller PP: Formaldehyde fixation. J Histochem Cytochem. 1985, 33 (8): 845-853. 10.1177/33.8.3894502.CrossRefPubMed
7.
Dimenstein IB: A Pragmatic Approach to Formalin Safety in Anatomical Pathology. Labmed. 2009, 40: 740-746.
8.
Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR: Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol. 2002, 160 (2): 449-457. 10.1016/S0002-9440(10)64864-X.CrossRefPubMedPubMedCentral
9.
Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK, Niu S, Zhao Y, Petricoin EF, Emmert-Buck MR: Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics. 2003, 3 (4): 413-421. 10.1002/pmic.200390056.CrossRefPubMed
10.
Cox ML, Schray CL, Luster CN, Stewart ZS, Korytko PJ, KN MK, Paulauskis JD, Dunstan RW: Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol. 2006, 80 (2): 183-191. 10.1016/j.yexmp.2005.10.002.CrossRefPubMed
11.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed
12.
Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004, 101 (5): 894-904. 10.1002/cncr.20480.CrossRefPubMed
13.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009, 360 (13): 1320-1328. 10.1056/NEJMoa0810084.CrossRefPubMed
14.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360 (13): 1310-1319. 10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral
15.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY: The genomic complexity of primary human prostate cancer. Nature. 470 (7333): 214-220.
16.
Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009, 55 (6): 1321-1330. 10.1016/j.eururo.2009.02.028.CrossRefPubMed
17.
Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ: Acceptance and Durability of Surveillance as a Management Choice in Men with Screen-Detected, Low-Risk Prostate Cancer: Improved Outcomes with Stringent Enrollment Criteria. Urology. 2011, 77 (4): 980-984. 10.1016/j.urology.2010.09.063.CrossRefPubMed
18.
O'Toole S A, Selinger CI, Millar EK, Lum T, Beith JM: Molecular assays in breast cancer pathology. Pathology. 43 (2): 116-127.
19.
Kelley RK, Van Bebber SL, Phillips KA, Venook AP: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 9 (1): 13-25.
20.
Turaga K, Acs G, Laronga C: Gene expression profiling in breast cancer. Cancer Control. 17 (3): 177-182.
21.
Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW: Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev. 2009, 18 (10): 2717-2722. 10.1158/1055-9965.EPI-09-0068.CrossRefPubMed
22.
Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, Astacio T, Canning S, Quijano J, Guinto W, Leibovich BC, Nelson JB, Vargo J, Wang Y, Wuxiong C: Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol. 2009, 182 (3): 1186-1193. 10.1016/j.juro.2009.05.003.CrossRefPubMed
23.
Hoque MO: DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn. 2009, 9 (3): 243-257. 10.1586/erm.09.10.CrossRefPubMedPubMedCentral
24.
Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA: Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008, 17 (7): 1682-1688. 10.1158/1055-9965.EPI-08-0044.CrossRefPubMedPubMedCentral
25.
Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C: Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol. 2009, 182 (1): 125-132. 10.1016/j.juro.2009.02.135.CrossRefPubMed
26.
Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, Fernandez G, Mesa-Tejada R, Teverovskiy M, Reuter VE, Scardino PT, Cordon-Cardo C: Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol. 2008, 26 (24): 3923-3929. 10.1200/JCO.2007.15.3155.CrossRefPubMed
27.
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009, 457 (7231): 910-914. 10.1038/nature07762.CrossRefPubMedPubMedCentral
28.
Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 2008, 60 (3): 510-516. 10.1002/mrm.21694.CrossRefPubMedPubMedCentral
29.
Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J: Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med. 2008, 60 (1): 33-40. 10.1002/mrm.21647.CrossRefPubMedPubMedCentral
30.
Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED: The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate. 2008, 68 (6): 620-628. 10.1002/pros.20727.CrossRefPubMed
31.
Mueller-Lisse UG, Scherr MK: Proton MR spectroscopy of the prostate. Eur J Radiol. 2007, 63 (3): 351-360. 10.1016/j.ejrad.2007.06.024.CrossRefPubMed
32.
Jordan KW, Cheng LL: NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev Proteomics. 2007, 4 (3): 389-400. 10.1586/14789450.4.3.389.CrossRefPubMed
33.
Costello LC, Franklin RB: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006, 5: 17-29. 10.1186/1476-4598-5-17.CrossRefPubMedPubMedCentral
34.
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ: Circulating tumor cells: evolving evidence and future challenges. Oncologist. 2009, 14 (11): 1070-1082. 10.1634/theoncologist.2009-0094.CrossRefPubMed
35.
Eschwege P, Moutereau S, Droupy S, Douard R, Gala JL, Benoit G, Conti M, Manivet P, Loric S: Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer. 2009, 100 (4): 608-610. 10.1038/sj.bjc.6604912.CrossRefPubMedPubMedCentral
36.
Okegawa T, Nutahara K, Higashihara E: Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009, 181 (3): 1091-1097. 10.1016/j.juro.2008.11.015.CrossRefPubMed
37.
Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008, 179 (6): 2187-2191. 10.1016/j.juro.2008.01.102.CrossRefPubMed
38.
Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007, 13 (23): 7053-7058. 10.1158/1078-0432.CCR-07-1506.CrossRefPubMed
39.
Crehange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM: Tumor Volume and Metabolism of Prostate Cancer Determined by Proton Magnetic Resonance Spectroscopic Imaging at 3T Without Endorectal Coil Reveal Potential Clinical Implications in the Context of Radiation Oncology. Int J Radiat Oncol Biol Phys. 2010, 80 (4): 1087-1094.CrossRefPubMed
40.
Zakian KL, Shukla-Dave A, Ackerstaff E, Hricak H, Koutcher JA: 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark. 2008, 4 (4-5): 263-276.PubMed
41.
Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J: Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006, 55 (6): 1257-1264. 10.1002/mrm.20909.CrossRefPubMed
42.
Schipper RG, Romijn JC, Cuijpers VM, Verhofstad AA: Polyamines and prostatic cancer. Biochem Soc Trans. 2003, 31 (2): 375-380. 10.1042/BST0310375.CrossRefPubMed
43.
Oyama T, Allsbrook WC, Kurokawa K, Matsuda H, Segawa A, Sano T, Suzuki K, Epstein JI: A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States. Arch Pathol Lab Med. 2005, 129 (8): 1004-1010.PubMed
44.
Netto GJ, Eisenberger M, Epstein JI: Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 multinational clinical trial. Urology. 77 (5): 1155-1160.
45.
Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI: Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol. 2001, 32 (1): 81-88. 10.1053/hupa.2001.21135.CrossRefPubMed
46.
Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI: Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001, 32 (1): 74-80. 10.1053/hupa.2001.21134.CrossRefPubMed
47.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351 (27): 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
48.
Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA: Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008, 132 (12): 1929-1935.PubMed
49.
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE: Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009, 8 (1): 113-117. 10.1021/pr800545q.CrossRefPubMedPubMedCentral
50.
McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ: SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008, 54 (1): 53-60.CrossRefPubMed
51.
Vandromme MJ, Umphrey H, Krontiras H: Image-guided methods for biopsy of suspicious breast lesions. J Surg Oncol. 103 (4): 299-305.
52.
Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA: Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol. 194 (1): 266-269.
53.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353 (16): 1659-1672. 10.1056/NEJMoa052306.CrossRefPubMed
54.
Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009, 81 (16): 6656-6667. 10.1021/ac901536h.CrossRefPubMed
55.
Dehaven CD, Evans AM, Dai H, Lawton KA: Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform. 2010, 2 (1): 9-10.1186/1758-2946-2-9.CrossRefPubMedPubMedCentral
Metadata
Title
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue
Authors
Jeffrey R Shuster
Raymond S Lance
Dean A Troyer
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Clinical Pathology / Issue 1/2011
Electronic ISSN: 1472-6890
DOI
https://doi.org/10.1186/1472-6890-11-14

Other articles of this Issue 1/2011

BMC Clinical Pathology 1/2011 Go to the issue

Research article

Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing

Research article

Hemoglobin estimation by the HemoCue® portable hemoglobin photometer in a resource poor setting

Research article

Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia

Research article

Decrease in thyroid adenoma associated (THADA) expression is a marker of dedifferentiation of thyroid tissue

Research article

Cortisol in hair measured in young adults - a biomarker of major life stressors?

Research article

Effects of different centrifugation conditions on clinical chemistry and Immunology test results
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits